Preliminary Evaluation of Atezolizumab Plus Bevacizumab As Salvage Treatment for Recurrent Hepatocellular Carcinoma after Liver Transplantation

Zhe Yang,Jin Sun,Zhuang Li,Haibo Mou,Shusen Zheng
DOI: https://doi.org/10.1002/lt.26416
2022-01-01
Liver Transplantation
Abstract:Liver TransplantationEarly View Letters to the Editor Preliminary Evaluation of Atezolizumab plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation Zhe Yang M.D., Ph.D., Zhe Yang M.D., Ph.D. Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorJingqi Sun M.D., Jingqi Sun M.D. Division of Hepatobiliary Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorLi Zhuang M.D., Li Zhuang M.D. Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHaibo Mou M.D., Haibo Mou M.D. Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorShusen Zheng M.D., Ph.D., F.A.C.S., Corresponding Author Shusen Zheng M.D., Ph.D., F.A.C.S. shusenzheng@zju.edu.cn orcid.org/0000-0003-1459-8261 Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, China Division of Hepatobiliary Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Address reprint requests to Shusen Zheng, M.D., Ph.D., F.A.C.S., Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, 848 Dongxin Road, Hangzhou 310000, P.R. China. Telephone/FAX: +86-571-87230000; E-mail: shusenzheng@zju.edu.cnSearch for more papers by this author Zhe Yang M.D., Ph.D., Zhe Yang M.D., Ph.D. Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorJingqi Sun M.D., Jingqi Sun M.D. Division of Hepatobiliary Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorLi Zhuang M.D., Li Zhuang M.D. Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHaibo Mou M.D., Haibo Mou M.D. Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorShusen Zheng M.D., Ph.D., F.A.C.S., Corresponding Author Shusen Zheng M.D., Ph.D., F.A.C.S. shusenzheng@zju.edu.cn orcid.org/0000-0003-1459-8261 Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, China Division of Hepatobiliary Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Address reprint requests to Shusen Zheng, M.D., Ph.D., F.A.C.S., Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, 848 Dongxin Road, Hangzhou 310000, P.R. China. Telephone/FAX: +86-571-87230000; E-mail: shusenzheng@zju.edu.cnSearch for more papers by this author First published: 28 January 2022 https://doi.org/10.1002/lt.26416 Natural Science Foundation of Zhejiang Province (Y21H160259). Ethical approval: All patients’ consents have been acquired. Potential conflict of interest: Nothing to report. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Early ViewOnline Version of Record before inclusion in an issue RelatedInformation
What problem does this paper attempt to address?